Meghan Peters, | |
1088 Augusta Farms Rd, Stuarts Draft, VA 24477-3200 | |
(540) 946-7611 | |
Not Available |
Full Name | Meghan Peters |
---|---|
Gender | Female |
Speciality | Occupational Therapist |
Location | 1088 Augusta Farms Rd, Stuarts Draft, Virginia |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1689459075 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225X00000X | Occupational Therapist | 0119007046 (Virginia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Meghan Peters, 1088 Augusta Farms Rd, Stuarts Draft, VA 24477-3200 Ph: (540) 946-7611 | Meghan Peters, 1088 Augusta Farms Rd, Stuarts Draft, VA 24477-3200 Ph: (540) 946-7611 |
News Archive
The Bend Memorial Clinic is recruiting patients for a Phase III lung cancer trial aimed at preventing the disease's recurrence in previously treated patients. Specifically, the trial is evaluating the potential of an immunotherapy called Antigen-Specific Cancer Immunotherapeutic (ASCI) for the treatment of Non-Small Cell Lung Cancer (NSCLC).
Doctors already know that weight loss can be an effective treatment for improving sleep apnea, although the reasons for this have remained unclear. Now, new research has uncovered that a reduction in tongue fat is the key to why fat loss helps in instances of Obstructive Sleep Apnea (OSA).
Alpha-adrenergic medication can significantly improve the quality of life of obese men with lower urinary tract symptoms, show study findings.
The Centers for Disease Control and Prevention (CDC) in the United States has linked the death of a four-week-old baby in Florida earlier this year to a pet turtle.
Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 "BRAF Inhibitor in Melanoma" (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.
› Verified 4 days ago